JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.

Launched by GUANGZHOU JOYO PHARMA CO., LTD ·

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called JYP0322 for people with a type of lung cancer known as non-small cell lung cancer (NSCLC) that has a specific change in a gene called ROS1. The study will compare how well JYP0322 works versus standard chemotherapy that uses platinum-based drugs in patients whose cancer has already been treated with a type of medicine called ROS1-TKIs (targeted therapies). The main goal is to see which treatment helps patients live longer without their cancer getting worse.

The trial is open to adults aged 18 to 74 of any gender who have this type of lung cancer and have been treated before with ROS1-TKI medicines. If you join the study, you will either receive JYP0322 or standard chemotherapy. If the chemotherapy stops working, you will have the option to switch to JYP0322 or discuss other treatment choices with your doctor. This study is not yet recruiting participants but aims to offer new options for patients whose cancer has progressed after previous treatments.

Gender

ALL

Eligibility criteria